Ticker

Cocrystal Pharma, Inc. (NASDAQ: COCP - Get Free Report)'s stock price traded up 2% during mid-day trading on Monday. The stock traded as high as $1.0338 and last traded at $1.03. 48,239 shares changed hands during mid-day trading, an increase of 32% from the average session volume of 36,633 shares. The stock had previously closed

CDI-988 is a direct-acting, oral antiviral being developed for norovirus Norovirus challenge study is underway at Emory University School of Medicine to evaluate efficacy and safety of CDI-988 No approved treatments or vaccines are available for norovirus treatment and prevention, posing a significant unmet need and contributing to a global economic burden of $60 billion annually BOTHELL, Wash., March 09, 2026…

BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that initial progress of a norovirus challenge study with its direct-acting, oral protease inhibitor CDI-988 will be presented at the 39th International Conference on Antiviral Research (ICAR2026), being held April 27–May 1 in Prague, Czech Republic. CDI-988 is the first oral antiviral…

Cocrystal Pharma, Inc. (NASDAQ: COCP - Get Free Report) Director Phillip Md Et Al Frost bought 20,000 shares of Cocrystal Pharma stock in a transaction on Tuesday, December 30th. The stock was acquired at an average cost of $0.97 per share, with a total value of $19,400.00. Following the acquisition, the director owned 1,788,551 shares of